Quince Therapeutics released FY2024 9 Months earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -10.2987

Brief Summary

On November 13, 2024 (US Eastern Time), Quince Therapeutics reported its fiscal 2024 third-quarter results, posting zero revenue, a net loss of $44.37 million, and an earnings per share (EPS) of -$10.2987.

Impact of The News

Analysis of Quince Therapeutics’ Q3 2024 Financial Report